AlphaStocks

HRMY vs KRYS

As of Sep 20, 2026, Harmony Biosciences Holdings (HRMY) scores 7.5/10 and Krystal Biotech (KRYS) 5.5/10 on AlphaStocks' five-model composite, so HRMY scores higher. KRYS trades 54% above its model fair value.

HRMY

Harmony Biosciences Holdings, Inc.

7.5

Strong Buy

$42.06

KRYS

Krystal Biotech, Inc.

5.5

Consider Buy

$336.82

HRMY vs KRYS: Which is the Better Investment?

Harmony Biosciences Holdings, Inc. (HRMY) scores 7.5/10 while Krystal Biotech, Inc. (KRYS) scores 5.5/10 on AlphaStocks' composite model. Harmony Biosciences Holdings, Inc. has the higher composite rating of Strong Buy. On a P/E basis, Harmony Biosciences Holdings, Inc. trades at 15.5x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricHRMYKRYS
Scores & Fundamentals
Composite Score7.5/105.5/10
RatingStrong BuyConsider Buy
Price$42.06$336.82
P/E Ratio15.549.3
ROE18.6%17.2%
Market Cap$2B$10B
Fair Value$218.10
Dividend Yield
Sector Rank#5 of 168#75 of 168
Model Verdicts
PiotroskiAttractiveAttractive
BuffettAttractiveNeutral
GrahamNeutralCaution
LynchStrongLimited Data
GreenblattStrongLimited Data
View full HRMYanalysis →View full KRYSanalysis →

Related comparisons

Compare any two stocks →

HRMY vs KRYS: Which Stock Scores Higher?

Harmony Biosciences Holdings, Inc. (HRMY) and Krystal Biotech, Inc. (KRYS) are both in the Health Care sector. HRMY currently leads with a composite score of 7.5/10 (Strong Buy) compared to KRYS's 5.5/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer